{"database": "lobbying", "table": "lobbying_filings_raw", "rows": [["e062ffc0-e953-4665-bf4e-8716ddbfb040", "Q3", 15042, "FOLEY & LARDNER LLP", 120768, "NOVOCURE INC.", 2020, "third_quarter", "2020-10-18T22:44:57.873000-04:00", 100000.0, 0, 0, 0, "{\"url\": \"https://lda.senate.gov/api/v1/filings/e062ffc0-e953-4665-bf4e-8716ddbfb040/\", \"filing_uuid\": \"e062ffc0-e953-4665-bf4e-8716ddbfb040\", \"filing_type\": \"Q3\", \"filing_type_display\": \"3rd Quarter - Report\", \"filing_year\": 2020, \"filing_period\": \"third_quarter\", \"filing_period_display\": \"3rd Quarter (July 1 - Sep 30)\", \"filing_document_url\": \"https://lda.senate.gov/filings/public/filing/e062ffc0-e953-4665-bf4e-8716ddbfb040/print/\", \"filing_document_content_type\": \"text/html\", \"income\": \"100000.00\", \"expenses\": null, \"expenses_method\": null, \"expenses_method_display\": null, \"posted_by_name\": \"Theodore Bornstein\", \"dt_posted\": \"2020-10-18T22:44:57.873000-04:00\", \"termination_date\": null, \"registrant_country\": \"United States of America\", \"registrant_ppb_country\": null, \"registrant_address_1\": \"3000 K Street NW\", \"registrant_address_2\": \"Suite 600\", \"registrant_different_address\": false, \"registrant_city\": \"Washington\", \"registrant_state\": \"DC\", \"registrant_zip\": \"20007\", \"registrant\": {\"id\": 15042, \"url\": \"https://lda.senate.gov/api/v1/registrants/15042/\", \"house_registrant_id\": 33563, \"name\": \"FOLEY & LARDNER LLP\", \"description\": \"law firm\", \"address_1\": \"3000 K Street NW\", \"address_2\": \"Suite 600\", \"address_3\": null, \"address_4\": null, \"city\": \"Washington\", \"state\": \"DC\", \"state_display\": \"District of Columbia\", \"zip\": \"20007\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"contact_name\": \"JARED B. RIFIS\", \"contact_telephone\": \"+1 202-295-4154\", \"dt_updated\": \"2026-01-30T13:33:06.842869-05:00\"}, \"client\": {\"id\": 120768, \"url\": \"https://lda.senate.gov/api/v1/clients/120768/\", \"client_id\": 1005445, \"name\": \"NOVOCURE INC.\", \"general_description\": \"Commercial stage oncology dedicated to advancement of TTF therapy to treat solid tumors\", \"client_government_entity\": false, \"client_self_select\": null, \"state\": \"NH\", \"state_display\": \"New Hampshire\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_state\": \"NH\", \"ppb_state_display\": \"New Hampshire\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"effective_date\": \"2017-10-10\"}, \"lobbying_activities\": [{\"general_issue_code\": \"HCR\", \"general_issue_code_display\": \"Health Issues\", \"description\": \"â\\u20ac\\u2039Advocate for client before members of the U.S. House of Representatives, U.S. Senate, and staffs to each, and before the Department of Health and Human Services, sub-agencies, and staffs to each, with respect to coverage and pricing issues; review relevant statutes and regulations regarding same.\", \"foreign_entity_issues\": \"Novocure Limited, identified on Form LD-1, owns 100% of Novocure, Inc.\", \"lobbyists\": [{\"lobbyist\": {\"id\": 67114, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"MICHAEL\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"CROSSEN\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 34, \"name\": \"Health & Human Services, Dept of (HHS)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"MAN\", \"general_issue_code_display\": \"Manufacturing\", \"description\": \"Advocate for client before members of the U.S. House of Representatives, U.S. Senate, and staffs to each, and before the Department of Health and Human Services, sub-agencies, and staffs to each, with respect to coverage and pricing issues; review relevant statutes and regulations regarding same.\", \"foreign_entity_issues\": \"Novocure Limited, identified on Form LD-1, owns 100% of Novocure, Inc.\", \"lobbyists\": [{\"lobbyist\": {\"id\": 67114, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"MICHAEL\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"CROSSEN\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 34, \"name\": \"Health & Human Services, Dept of (HHS)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"VET\", \"general_issue_code_display\": \"Veterans\", \"description\": \"Advocate for client before members of the U.S. House of Representatives, U.S. Senate, and staffs to each, and before the Department of Health and Human Services, sub-agencies, and staffs to each, with respect to coverage and pricing issues; review relevant statutes and regulations regarding same.\", \"foreign_entity_issues\": \"Novocure Limited, identified on Form LD-1, owns 100% of Novocure, Inc.\", \"lobbyists\": [{\"lobbyist\": {\"id\": 67114, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"MICHAEL\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"CROSSEN\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 34, \"name\": \"Health & Human Services, Dept of (HHS)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"MMM\", \"general_issue_code_display\": \"Medicare/Medicaid\", \"description\": \"Advocate for client before members of the U.S. House of Representatives, U.S. Senate, and staffs to each, and before the Department of Health and Human Services, sub-agencies, and staffs to each, with respect to coverage and pricing issues; review relevant statutes and regulations regarding same.\", \"foreign_entity_issues\": \"Novocure Limited, identified on Form LD-1, owns 100% of Novocure, Inc.\", \"lobbyists\": [{\"lobbyist\": {\"id\": 67114, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"MICHAEL\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"CROSSEN\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 34, \"name\": \"Health & Human Services, Dept of (HHS)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"BUD\", \"general_issue_code_display\": \"Budget/Appropriations\", \"description\": \"â\\u20ac\\u2039Advocate for client before members of the U.S. House of Representatives, U.S. Senate, and staffs to each, and before the Department of Health and Human Services, sub-agencies, and staffs to each, with respect to coverage and pricing issues; review relevant statutes and regulations regarding same.\", \"foreign_entity_issues\": \"Novocure Limited, identified on Form LD-1, owns 100% of Novocure, Inc.\", \"lobbyists\": [{\"lobbyist\": {\"id\": 67114, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"MICHAEL\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"CROSSEN\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 34, \"name\": \"Health & Human Services, Dept of (HHS)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"CPT\", \"general_issue_code_display\": \"Copyright/Patent/Trademark\", \"description\": \"Advocate for client before members of the U.S. House of Representatives, U.S. Senate, and staffs to each, and before the Department of Health and Human Services, sub-agencies, and staffs to each, with respect to coverage and pricing issues; review relevant statutes and regulations regarding same.\", \"foreign_entity_issues\": \"Novocure Limited, identified on Form LD-1, owns 100% of Novocure, Inc.\", \"lobbyists\": [{\"lobbyist\": {\"id\": 67114, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"MICHAEL\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"CROSSEN\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 34, \"name\": \"Health & Human Services, Dept of (HHS)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"INS\", \"general_issue_code_display\": \"Insurance\", \"description\": \"Advocate for client before members of the U.S. House of Representatives, U.S. Senate, and staffs to each, and before the Department of Health and Human Services, sub-agencies, and staffs to each, with respect to coverage and pricing issues; review relevant statutes and regulations regarding same.\", \"foreign_entity_issues\": \"Novocure Limited, identified on Form LD-1, owns 100% of Novocure, Inc.\", \"lobbyists\": [{\"lobbyist\": {\"id\": 67114, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"MICHAEL\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"CROSSEN\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 34, \"name\": \"Health & Human Services, Dept of (HHS)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"MED\", \"general_issue_code_display\": \"Medical/Disease Research/Clinical Labs\", \"description\": \"Advocate for client before members of the U.S. House of Representatives, U.S. Senate, and staffs to each, and before the Department of Health and Human Services, sub-agencies, and staffs to each, with respect to coverage and pricing issues; review relevant statutes and regulations regarding same.\", \"foreign_entity_issues\": \"Novocure Limited, identified on Form LD-1, owns 100% of Novocure, Inc.\", \"lobbyists\": [{\"lobbyist\": {\"id\": 67114, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"MICHAEL\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"CROSSEN\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 34, \"name\": \"Health & Human Services, Dept of (HHS)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}, {\"general_issue_code\": \"SCI\", \"general_issue_code_display\": \"Science/Technology\", \"description\": \"Advocate for client before members of the U.S. House of Representatives, U.S. Senate, and staffs to each, and before the Department of Health and Human Services, sub-agencies, and staffs to each, with respect to coverage and pricing issues; review relevant statutes and regulations regarding same.\", \"foreign_entity_issues\": \"Novocure Limited, identified on Form LD-1, owns 100% of Novocure, Inc.\", \"lobbyists\": [{\"lobbyist\": {\"id\": 67114, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"MICHAEL\", \"nickname\": null, \"middle_name\": null, \"last_name\": \"CROSSEN\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 34, \"name\": \"Health & Human Services, Dept of (HHS)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}], \"conviction_disclosures\": [], \"foreign_entities\": [], \"affiliated_organizations\": []}"]], "columns": ["filing_uuid", "filing_type", "registrant_id", "registrant_name", "client_id", "client_name", "filing_year", "filing_period", "received_date", "amount_reported", "is_amendment", "is_no_activity", "is_termination", "raw_json"], "primary_keys": ["filing_uuid"], "primary_key_values": ["e062ffc0-e953-4665-bf4e-8716ddbfb040"], "units": {}, "query_ms": 23.40782608371228, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}